Ascendant Diagnostics Receives ASTA Investment for Breast Cancer Detection

Fayetteville biotech firm Ascendant Diagnostics has received a $300,000 investment from the Arkansas Science & Technology Authority for development of its MelodyDX product that uses tear samples to screen for breast cancer.

Want the Full Article?

Get Unlimited Archive Access for $19.95 per Year

Readers must pay to access stories older than 20 days.

Purchase Now

Already have archive access? Login to view this article.